Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted a patent to Pearl Therapeutics' co-suspension formulation technology for inhaled combinations.
Subscribe to our email newsletter
The Patent No. 8,324,266 covers methods for treating pulmonary disease using Pearl’s co-suspension technology in metered-dose inhalers (MDIs).
The technology is used in PT003, a fixed dose combination of glycopyrrolate (GP) and formoterol fumarate (FF), as well as PT010, a triple-combination of GP, FF and an inhaled corticosteroid.
Pearl Therapeutics chief executive officer Chuck Bramlage said the patency period until 2030 provides the company with control for the long-term commercial value of its combination product portfolio, including PT003.
"This patent marks the rapid evolution of Pearl’s intellectual property beyond the patent portfolio in-licensed in 2007," Bramlage added.
"With the recent completion of PT003’s Phase 2 program, we are preparing to advance it into Phase 3 in 2013, and subsequently to bring to market this valuable therapy for the millions of individuals whose COPD is inadequately controlled with current medications," Bramlage added.